Quince Therapeutics names Brigette Roberts CEO in management reshuffle

• Quince Therapeutics disclosed conditional resignations by CEO and Chief Medical Officer Dirk Thye, effective two business days after a Sept. 25, 2026 special meeting.
• COO, Chief Business Officer, and Chief Compliance Officer Brendan Hannah also tendered a conditional resignation on the same timeline.
• Brigette Roberts was conditionally named CEO; she has served as chief of corporate affairs and a director since the Orphai acquisition.
• John Militello was conditionally named CFO; he joined Orphai as head of finance in July 2026, previously holding senior finance roles at Rocket Pharmaceuticals.
• Keith Fandrick was conditionally named COO; he has led technical operations since the acquisition, previously serving as Orphai’s COO.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-328784), on July 31, 2026, and is solely responsible for the information contained therein.